Correlates of antidepressant and anxiolytic, hypnotic or sedative medication use in an Australian community sample

Australian and New Zealand Journal of Psychiatry

Volumn 45, Issue 3, 2011, Pages 249-260

  Harris, Meredith G ^a   Burgess, Philip M ^a   Whiteford, Harvey A ^a   Pirkis, Jane ^b   Siskind, Dan ^a   Slade, Tim ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

antidepressants; anxiolytics; hypnotics; mental disorders; sedatives

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; SEDATIVE AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; AUSTRALIA; CHRONIC DISEASE; CHRONIC PAIN; COMMUNITY SAMPLE; COMORBIDITY; DISTRESS SYNDROME; DRUG UTILIZATION; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENTAL DISEASE; MOOD DISORDER; MUSCULOSKELETAL DISEASE; OUTCOME VARIABLE; PHYSICAL DISEASE; SLEEP DISORDER; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; AUSTRALIA; DRUG UTILIZATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LOGISTIC MODELS; MALE; MENTAL DISORDERS; MIDDLE AGED;

EID: 79952288129     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2010.531459     Document Type: Article

References (50)

1. Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. Aust N Z J Psychiatry 2009; 43:594-605.
2. Andrews G, Tolkien II Team. Tolkien II: a needs-based, costed stepped-care model for mental health services. Sydney: World Health Organization Collaborating Centre for Classification of Mental Health, 2007.
3. Bandelow B, Zohar J, Hollander E, Kasper S, Jürgen Möller H. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry 2008; 9:248-312.
4. Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 2005; 25:141-150. (Pubitemid 40395092)
5. NICE. Guidance on the use of zalepon, zolpidem and zoplicone for the short-term management of insomnia. London: National Institute for Health and Clinical Excellence, 2004.
6. Hollingworth SA, Burgess PM, Whiteford HA. Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry 2010; 44:513-519.
7. Hollingworth S, Siskind D. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf 2010; 19:280-288.
8. Burgess PM, Pirkis JE, Slade TN, Johnston AK, Meadows GN, Gunn JM. Service use for mental health problems: findings from the 2007 National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry 2009; 43:615-623.
9. Mojtabai R. Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom 2008; 77:83-92.
10. Goldney R, Bain M. Prevalence of psychotropic use in a South Australian population. Australas Psychiatry 2006; 14:379-383. (Pubitemid 44762504)
11. Page AN, Swannell S, Martin G, Hollingworth S, Hickie IB, Hall WD. Sociodemographic correlates of antidepressant utilisation in Australia. Med J Aust 2009; 190:479-483.
12. Lagnaoui R, Depont F, Fourrier A, et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004; 60:523-529. (Pubitemid 39350165)
13. John U, Baumeister SE, Volzke H, Meyer C, Ulbricht S, Alte D. Sedative, hypnotic, anxiolytic and opioid medicament use and its co-occurrence with tobacco smoking and alcohol risk drinking in a community sample. BMC Public Health 2007; 7:337.
14. Colman I, Croudace TJ, Wadsworth ME, Jones PB. Factors associated with antidepressant, anxiolytic and hypnotic use over 17 years in a national cohort. J Affect Disord 2008; 110:234-240.
15. Wells KB, Kamberg C, Brook R, Camp P, Rogers W. Health status, sociodemographic factors, and the use of prescribed psychotropic drugs. Med Care 1985; 23:1295-1306. (Pubitemid 16255320)
16. Olfson M, Pincus HA. Use of benzodiazepines in the community. Arch Intern Med 1994; 154:1235-1240. (Pubitemid 24180481)
17. Blennow G, Romelsjo A, Leifman H, Leifman A, Karlsson G. Sedatives and hypnotics in Stockholm: social factors and kinds of use. Am J Public Health 1994; 84:242-246. (Pubitemid 24138459)
18. Beck CA, Patten SB, Williams JVA, et al. Antidepressant utili sation in Canada. Soc Psychiatry Psychiatr Epidemiol 2005; 40:799-807.
19. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002; 63:817-825.
20. Australian Bureau of Statistics. National Health Survey: users'guide-electronic publication, 2004-05. Canberra: Australian Bureau of Statistics, 2006.
21. World Health Organization. International statistical classification of diseases and related health problems, 10th revision. Geneva: World Health Organization, 1992.
22. Krueger RF. The structure of common mental disorders. Arch Gen Psychiatry 1999; 56:921-926. (Pubitemid 29480128)
23. Slade T, Watson D. The structure of common DSM-IV and ICD-10 mental disorders in the Australian general population. Psychol Med 2006; 36:1593-1600. (Pubitemid 44575805)
24. Teesson M, Slade T, Mills K. Comorbidity in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry 2009; 43:606-614.
25. Kessler R, Mroczek, D. Final versions of our Non-specific Psychological Distress Scale. Memo dated March 10 1994 . Ann Arbor, MI: Survey Research Center for Social Research, University of Michigan, 1994.
26. Australian Bureau of Statistics. Information paper: use of the Kessler Psychological Distress Scale in ABS health surveys, Australia, 2001. Canberra: Australian Bureau of Statistics, 2003.
27. Hawthorne G, Richardson J, Osborne R, McNeil H. The Assessment of Quality of Life (AQoL) instrument: construction, initial validation and utility scaling. Working paper 76. Melbourne: Centre for Health Program Evaluation, 1997.
28. National Health Priority Action Council. F uture directions of the National Health Priority Areas initiative. Report to the Australian Health Ministers' Advisory Council October 2002 . Canberra: Department of Health and Ageing, 2002.
29. Australian Bureau of Statistics. Information paper: an introduction to socio- economic indexes for areas (SEIFA), 2006. Canberra: Australian Bureau of Statistics, 2008.
30. Australian Bureau of Statistics. Technical manual: National Survey of Mental Health and Wellbeing, confidentialised unit record files 2007. Canberra: Australian Bureau of Statistics, 2009.
31. StataCorp. Stata Statistical Software: Release 11. StataCorp; 2009.
32. Australian Bureau of Statistics. 2007-2008 National Health Survey: summary of results. Canberra: Australian Bureau of Statistics, 2009.
33. Scott KM, Von Korff M, Alonso J, et al. Mental-physical co-morbidity and its relationship with disability: results from the World Mental Health Surveys. Psychol Med 2009; 39:33-43.
34. Australian Government Department of Health and Ageing. Australian statistics on medicine 2008. Canberra: Commonwealth of Australia, 2009.
35. Alonso J, Angermeyer MC, Bernert S, et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004:55-64.
36. Merikangas K, Ames M, Cui L, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry 2007; 64:1180-1188. (Pubitemid 47529342)
37. Australian Institute of Health and Welfare. Mental health services in Australia, 2006-07. Canberra: Australian Institute of Health and Welfare, 2009.
38. Australian Bureau of Statistics. 2004-2005 National Health Survey: summary of results Australia. Canberra: Australian Bureau of Statistics, 2006.
39. Bebbington PE, Brugha TS, Meltzer H, et al. Neurotic disorders and the receipt of psychiatric treatment. Psychol Med 2000; 30:1369-1376.
40. Culberson JW, Ziska M. Prescription drug misuse/abuse in the elderly. Geriatrics 2008; 63:22-31.
41. Reavley NJ, Cvetkovski S, Jorm AF, Lubman DI. Help-seeking for substance use, anxiety and affective disorders among young people: results form the 2007 National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry 2010; 44:729-735.
42. Parslow RA, Jorm AF. Who uses mental health services in Australia? An analysis of data from the National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry 2000; 34:997-1008.
43. Kessler RC, Demler O, Frank RG , et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005; 352:2515-2523.
44. Wang PS, Demler O, Olfson M, Pincus HA, Wells KB, Kessler RC. Changing profiles of service sectors used for mental health care in the United States. Am J Psychiatry 2006; 163:1187-1198. (Pubitemid 44464446)
45. Bramesfeld A, Grobe T, Schwartz FW. Who is treated, and how, for depression? An analysis of statutory health insurance data in Germany. Soc Psychiatry Psychiatr Epidemiol 2007; 42:740-746.
46. Parslow RA, Jorm AF. Predictors of types of help provided to people using services for mental health problems: an analysis of the Australian National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry 2001; 35:183-189. (Pubitemid 32377536)
47. Issakidis C, Andrews G. Who treats whom? An application of the Pathways to Care model in Australia. Aust N Z J Psychiatry 2006; 40:74-86. (Pubitemid 43337446)
48. Harman JS, Edlund MJ, Fortney JC. Disparities in the adequacy of depression treatment in the United States. Psychiatr Serv 2004; 55:1379-1385. (Pubitemid 39577973)
49. Issakidis C, Andrews G. Service utilisation for anxiety in an Australian community sample. Soc Psychiatry Psychiatr Epidemiol 2002; 37:153-163. (Pubitemid 36076004)
50. Morin C, Bootzin R, Buysse D, Edinger J, Espie C, Lichstein K. Psychological and behavioral treatment of insomnia:update of the recent evidence (1998-2004). Sleep 2006; 29:1398-1414.